All news

JP Morgan upgrades CME Group to overweight

Alpha Vantage · Benzinga · · AI-summarised by FinFlash

JP Morgan upgraded CME Group Inc. (NASDAQ: CME) from Underweight to Overweight with a $367 price target, one of four notable analyst upgrades. BMO Capital raised Ionis Pharmaceuticals, Argus Research lifted Equifax and Citizens upgraded Omega Healthcare Investors. Consensus sits at 8 Buy, 5 Hold and 3 Sell ratings. The CME upgrade signals renewed confidence in exchange operators for investors.

Read original source

CME company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.